All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Jane Churpek, The University of Wisconsin, Madison, US. She talked about how people with familial RUNX1 germline mutations should be monitored?
Experts suggest monitoring the blood count every 6-12 months and potentially carrying out a baseline bone marrow biopsy. However many questions remain, including the need for molecular testing to monitor the acquisition of additional mutations, or whether the presence of a single additional mutation would impact on patients outcomes.
How should family members with familial RUNX1 germline mutations be monitored?
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox